Orbital Therapeutics, a secretive startup pioneering circular RNA technology, released its first preclinical data demonstrating in vivo CAR-T cell therapy potential in non-human primates. The technology represents a next generation of mRNA therapeutics by enabling circular structures that may enhance stability and expression duration. Orbital’s progress positions it competitively in the growing cell and gene therapy arena, with advancements set to be presented at an upcoming conference. Details remain limited as Orbital maintains a low public profile while scaling its novel RNA platform.